[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100538952":3},{"organization":4,"armGroups":7,"interventions":18,"overallOfficials":25,"centralContacts":30,"locations":37,"responsibleParty":111,"collaborators":24,"id":113,"slug":114,"hasResults":115,"nctId":116,"briefTitle":117,"officialTitle":118,"acronym":24,"eligibilityCriteria":119,"healthyVolunteers":115,"sex":120,"minAge":121,"maxAge":24,"enrollmentInfo":122,"targetDuration":24,"studyType":125,"phases":126,"briefSummary":128,"conditions":129,"keywords":24,"overallStatus":40,"whyStopped":24,"lastUpdateSubmitDate":131,"lastUpdatePostDateStruct":132,"startDateStruct":135,"completionDateStruct":137,"leadSponsor":139,"locationsCount":140},{"fullName":5,"class":6},"Step Pharma, SAS","INDUSTRY",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"Phase 1a (Part 1, Dose Escalation)","EXPERIMENTAL","Up to 5 dose levels with STP938 administered as oral monotherapy",[13],"Drug: STP938",{"label":15,"type":10,"description":16,"interventionNames":17},"Phase 1b (Part 2, Safety Expansion)","Further evaluation of STP938 administered as oral monotherapy at the RP2D",[13],[19],{"type":20,"name":21,"description":22,"armGroupLabels":23,"otherNames":24},"DRUG","STP938","Small molecule",[9,15],null,[26],{"name":27,"affiliation":28,"role":29},"Maureen Higgins","Step Pharma","STUDY_DIRECTOR",[31,35],{"name":27,"role":32,"phone":33,"phoneExt":24,"email":34},"CONTACT","+33 1 86 26 43 56","STP938-201@step-ph.com",{"name":36,"role":32,"phone":33,"phoneExt":24,"email":34},"Duc Tran",[38,52,62,71,83,94,102],{"facility":39,"status":40,"city":41,"state":42,"zip":43,"country":44,"countryCode":45,"cosmosGeoPoint":46,"geoPoint":51,"contacts":24},"Comprehensive Hematology Oncology, LLC","RECRUITING","St. Petersburg","Florida","33709","United States","US",{"type":47,"coordinates":48},"Point",[49,50],-82.67927,27.77086,{"lat":50,"lon":49},{"facility":53,"status":40,"city":54,"state":55,"zip":56,"country":44,"countryCode":45,"cosmosGeoPoint":57,"geoPoint":61,"contacts":24},"Mary Crowley Cancer Research Center","Dallas","Texas","75251",{"type":47,"coordinates":58},[59,60],-96.80667,32.78306,{"lat":60,"lon":59},{"facility":63,"status":40,"city":64,"state":55,"zip":65,"country":44,"countryCode":45,"cosmosGeoPoint":66,"geoPoint":70,"contacts":24},"Next Oncology","San Antonio","78292",{"type":47,"coordinates":67},[68,69],-98.49363,29.42412,{"lat":69,"lon":68},{"facility":72,"status":40,"city":73,"state":74,"zip":75,"country":76,"countryCode":77,"cosmosGeoPoint":78,"geoPoint":82,"contacts":24},"Institut Gustave Roussy","Villejuif","Paris","94805","France","FR",{"type":47,"coordinates":79},[80,81],2.35992,48.7939,{"lat":81,"lon":80},{"facility":84,"status":40,"city":85,"state":85,"zip":86,"country":87,"countryCode":88,"cosmosGeoPoint":89,"geoPoint":93,"contacts":24},"The Beatson Institute for Cancer Research","Glasgow","G12 8QQ","United Kingdom","UK",{"type":47,"coordinates":90},[91,92],-4.25763,55.86515,{"lat":92,"lon":91},{"facility":95,"status":40,"city":96,"state":24,"zip":24,"country":87,"countryCode":88,"cosmosGeoPoint":97,"geoPoint":101,"contacts":24},"University College London","London",{"type":47,"coordinates":98},[99,100],-0.12574,51.50853,{"lat":100,"lon":99},{"facility":103,"status":40,"city":104,"state":24,"zip":105,"country":87,"countryCode":88,"cosmosGeoPoint":106,"geoPoint":110,"contacts":24},"The Christie","Manchester","M20 4BX",{"type":47,"coordinates":107},[108,109],-2.23743,53.48095,{"lat":109,"lon":108},{"type":112,"investigatorFullName":24,"investigatorTitle":24,"investigatorAffiliation":24,"oldNameTitle":24,"oldOrganization":24},"SPONSOR","100538952","phase-1-study-of-stp938-dencatistat-in-advanced-solid-tumours-100538952",false,"NCT06297525","Study of STP938 (Dencatistat) in Advanced Solid Tumours","An Open-Label, Phase 1 Study to Evaluate Safety, Tolerability and Pharmacokinetics of the CTPS1 Inhibitor STP938 in Adult Subjects With Advanced Solid Tumors, With a Safety Expansion in Advanced CTPS2 Null Ovarian Cancer","Main Inclusion Criteria:\n\n* Signed and dated informed consent, and able to comply with the study procedures and any locally required authorization.\n* Male or female aged ≥ 18 years.\n* Advanced disease not curable by available therapies and requires systemic therapy.\n* Histologically confirmed diagnosis of eligible cancer type.\n* Must have tumor tissue available for biomarker testing.\n* Measurable disease (Part 1) and measurable disease per RECIST (Part2)\n* Eastern Cooperative Oncology Group (ECOG) performance status ≤2.\n* Life expectancy \\> 3 months as assessed by the Investigator.\n* Adequate organ function (bone marrow, hepatic, renal function and coagulation).\n* All toxicities (except alopecia) from prior cancer treatments or procedures must have resolved to ≤Grade 1 or returned to baseline levels prior to enrollment.\n\nMain Exclusion Criteria:\n\n* Pregnant or breastfeeding females and women of childbearing potential or males unwilling to comply with contraception requirements.\n* Known active or symptomatic CNS metastases, carcinomatous meningitis, leptomeningeal disease or a history of spinal cord compression\n* Active malignancy within 2 years of study enrollment\n* Prior radiation within 2 weeks of start of therapy.\n* Systemic cancer treatments, monoclonal antibody-directed therapies, other investigational agents within 4 weeks before enrollment, or \\\u003C5 half-lives since completion of previous investigational therapy, whichever is shorter.\n* Uncontrolled intercurrent illness.\n* Immunocompromised subjects with increased risk of opportunistic infections or history of opportunistic infection in the last 12 months.\n* Known active or chronic hepatitis B or active hepatitis C virus (HCV) infection.\n* Subjects with corrected QT interval \\>470 msec based on averaged triplicate electrocardiogram (ECG) readings at the Screening Visit using the QT interval corrected for heart rate using Fridericia's method (QTcF).","ALL","18 Years",{"count":123,"type":124},70,"ESTIMATED","INTERVENTIONAL",[127],"PHASE1","The Phase 1a part of the study is a dose escalation of STP938 as a monotherapy.\n\nThe Phase 1b part of the study is a safety expansion cohort of STP938 as a monotherapy.",[130],"Solid Tumor","2026-06-13",{"date":133,"type":134},"2026-06-16","ACTUAL",{"date":136,"type":134},"2024-08-02",{"date":138,"type":124},"2027-05",{"name":5,"class":6},7]